Theragenics Announces Supply And Reseller Agreement With Core Oncology

Buford, GA, January 12, 2010 – Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has signed an agreement with Core Oncology, Inc. for the distribution of TheraSeed® palladium-103 brachytherapy seeds. Under the terms of the agreement, Theragenics will be the exclusive palladium-103 seed supplier to Core for the treatment of prostate cancer in the U.S. and Canada. The term of the agreement is through November 30, 2011, and is automatically extended for additional one-year terms unless terminated by either party upon prior written notice.

“We are delighted to be partnering with Core as their exclusive supplier of palladium-103 seeds for prostate cancer treatment in the U.S. and Canada,” stated M. Christine Jacobs, Chairman and CEO of Theragenics. “As one of the largest palladium-103 seed distributors in the U.S. and an innovator in delivering total brachytherapy solutions to their customers, Core is a recognized leader in the industry.”

“TheraSeed® provides us with the industry’s leading palladium seed to compliment our industry leading iodine-125 product, ProstaSeed®,” stated Travis Gay, CEO and President of Core Oncology. “Theragenics is a recognized leader in brachytherapy and our new partnership should further Core’s goal of providing high quality and innovative products to our customers.”

About Theragenics
Theragenics Corporation (NYSE: TGX) operates two business segments: its brachytherapy seed business and its surgical products business. The brachytherapy business manufactures and markets its premier product, the palladium-103 TheraSeed® device (www.theraseed.com) and I-Seed, an iodine-125 based device, which are used primarily in the minimally invasive treatment of localized prostate cancer. The surgical products business (www.cpmedical.com, www.galtmedical.com, www.needletech.com) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, and other needle-based products. The surgical products segment serves a number of markets and applications, including, among other areas, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. For additional information, call our Investor Relations Department at (800) 998-8479 or visit www.theragenics.com.

About Core Oncology
Core Oncology was founded September 15, 2006 by the existing management of the brachytherapy business owned by Coloplast, formerly Mentor, for the sole purpose of enhancing the levels of service and continuing our pursuit of innovation within the field of Radiation Oncology. Our philosophy is to make our Customers and their trusted patients the focus of our business. Meeting their needs is our primary goal. This is how we derived our name Core Oncology, as our Customers and Patients are our center, our focus, our core.

On June 8, 2007, Core Oncology completed its acquisition of Mills Biopharmaceuticals LLC, the recently acquired brachytherapy division of Coloplast. Prior to this, the brachytherapy division was owned by Mentor Corporation. Initially formed in 1997, Mentor’s brachytherapy division entered the radiation oncology market as the first company to offer both iodine and palladium brachytherapy sources. Since then the division has developed and successfully launched numerous innovative delivery technologies and services, including the Isoloader® workstation, prescription loaded needle services and proprietary cartridge systems for the Mick® applicator. This division has maintained a track record of strong year-on-year growth in a highly competitive market space. The management team that has facilitated the growth and development of the brachytherapy division is the same team that now manages Core Oncology. This team has remained intact from the beginning of the business. We pride ourselves on the culture that we have established and the employee retention that has resulted.

To learn more about the tools and services Core Oncology provides, visit www.coreoncology.com.